Novo Nordisk

Novo Nordisk recalls sales rep samples sunk by Texas power outages
Novo Nordisk recalls sales rep samples sunk by Texas power outages
Fierce Pharma
Novo Nordisk
Texas
drug reps
Flag link:
Ahead of potential Ozempic approval in obesity, Novo hits 'full go mode' for launch, exec says
Ahead of potential Ozempic approval in obesity, Novo hits 'full go mode' for launch, exec says
Fierce Pharma
Novo Nordisk
Ozempic
drug launches
obesity
Flag link:
AbbVie's Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along
AbbVie's Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along
Fierce Pharma
AbbVie
Humira
DTC advertising
television ads
Sanofi
Dupixent
Novo Nordisk
Rybelsus
Flag link:
Novo Nordisk ups forecasts after Q1 profit boost
Novo Nordisk ups forecasts after Q1 profit boost
Pharmaforum
Novo Nordisk
earnings
Flag link:
Novo Nordisk to launch PhIII obesity trial for oral semaglutide
Novo Nordisk to launch PhIII obesity trial for oral semaglutide
Endpoints
Novo Nordisk
diabetes
obesity
semaglutide
oral semaglutide
clinical trials
Flag link:
Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking
Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking
Fierce Pharma
reputation
pharma industry
Sanofi
Novo Nordisk
Roche
Eli Lilly
Bristol Myers Squibb
Flag link:
Big pharma freshens up
Big pharma freshens up
EP Vantage
Merck
Bristol Myers Squibb
Astellas
Novo Nordisk
AbbVie
Sanofi
Flag link:
FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application
FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application
Benzinga
Novo Nordisk
FDA
diabetes
semaglutide
RTF letters
Flag link:
Gilead, Novo Nordisk push NASH cocktail deeper into the clinic
Gilead, Novo Nordisk push NASH cocktail deeper into the clinic
Fierce Biotech
Gilead Sciences
Novo Nordisk
NASH
R&D
Flag link:
GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts
GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts
Fierce Pharma
COVID-19
pandemic
GSK
Novo Nordisk
Roche
Flag link:
Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?
Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?
Fierce Pharma
Eli Lilly
tirzepatide
diabetes
Ozempic
Novo Nordisk
clinical trials
Flag link:
Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture
Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture
Fierce Biotech
Eli Lilly
Novo Nordisk
tirzepatide
semaglutide
type 2 diabetes
clinical trials
Flag link:
Watch out, Novo Nordisk. Lilly's new dual action diabetes med could pressure Ozempic: analyst
Watch out, Novo Nordisk. Lilly's new dual action diabetes med could pressure Ozempic: analyst
Fierce Pharma
Eli Lilly
tirzepatide
Novo Nordisk
Ozempic
diabetes
Flag link:
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Endpoints
Novo Nordisk
semaglutide
obesity
Flag link:
Novo Nordisk plots $1.3B in spending as it expands API production—and advances new oral meds
Novo Nordisk plots $1.3B in spending as it expands API production—and advances new oral meds
Fierce Pharma
Novo Nordisk
drug manufacturing
APIs
Flag link:
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Yahoo/Global Newswire
Novo Nordisk
FDA
Ozempic
type 2 diabetes
semaglutide
Flag link:
Pharma TV ad spenders blow up December with spendiest month of 2020
Pharma TV ad spenders blow up December with spendiest month of 2020
Fierce Pharma
television ads
AbbVie
Humira
Novo Nordisk
DTC ads
Flag link:
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Pharmaforum
Novo Nordisk
Dicerna
gene silencing
liver disease
Flag link:
Novo takes the plunge in Alzheimer’s
Novo takes the plunge in Alzheimer’s
EP Vantage
Novo Nordisk
Rybelsus
Alzheimer's disease
Flag link:
Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics
Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics
Endpoints
Novo Nordisk
Novo Holdings
Hemab
hemophilia
Flag link:

Pages